Implant Therapy After Taking Antiresorptive Drugs:A Case Report

Antiresorptive drugs (ARDs) are commonly used in the treatment of osteoporosis and may cause drug-related osteonecrosis of the jaw (MRONJ). The implantologist has to deal with the side effects of drugs in implant therapy and to take appropriate prognostic measures. A 24-year-old female presented to restore a missing tooth and who had been treated with the antiresorptive drug Desutumab for osteoporosis 2 months previously. After routine implanting procedures, intravenous antibiotics were administered 5 days to prevent postoperative infection. The CBCT results showed that the initial stability was poor, with more marginal bone resorption, and it was decided to extend the healing time, and the patient was instructed to take calcium tablets. After 8 months of postoperative follow-up, the patient was found to have good osseointegration, a healing abutment was placed, and a two-stage crown restoration was performed. The use of ARDs may have an impact on bone remodelling, but patients treated with low-dose short-term therapy have a good short-term prognosis and only exhibit poor initial stability, which can be treated aggressively with anti-infective therapy along with load reduction to promote osseointegration. However, the implantologist should remain vigilant in patients treated at high or low doses for long periods of time and use other restorative techniques if necessary. The prognosis for dental implant is favourable in patients treated with low-dose osteoporosis medication. However, long-term stability needs to be monitored.